Compare TG Therapeutics Inc (TGTX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Global X Uranium ETF — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Global X Uranium ETF trades at $40.8. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | URA | |
|---|---|---|
Market Cap | $8.26B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $59.06 | $61.81 |
52-Week Low | $26.39 | $36.45 |
Enterprise Value | $8.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
URA trades at $38.64, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages but oversold RSI signals. The ETF holds $6.29 billion in assets and benefits from strong narratives around AI-driven power demand and nuclear energy expansion, though key financial ratios are not publicly detailed for the fund itself. Recent news highlights uranium's role in meeting data center electricity needs.
Outlook is supported by structural demand trends, but high expense ratios and competition from pure-play uranium funds pose risks. The fund's performance hinges on uranium price movements and policy developments, with current technical weakness suggesting caution in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
